P50991 (TCPD_HUMAN) Homo sapiens (Human)

T-complex protein 1 subunit delta UniProtKBInterProSTRINGInteractive Modelling

539 aa; Sequence (Fasta) ; (Isoform 2); 5 identical sequences: Pongo abelii: H2P634; Pan troglodytes: K7CBP3, K7B850; Pan paniscus: A0A2R9BDI0; Nomascus leucogenys: G1RF78

Available Structures

49 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
cryo-EM structure of human TRiC-ADP-AlFx Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-539
10016×ADP; 16×MG; 16×AF3;
Human TRiC-tubulin-S3 Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-539
10016×ADP; 16×MG; 16×AF3;
cryo-EM structure of human TRiC-ATP-closed state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-539
100
Human TRiC-PhLP2A-actin complex in the closed state Heteromer
P17987; P40227; P48643; P49368; P50990; P60709; P78371; Q99832; Q9H2J4;
19-539
100
CCT G beta 5 complex closed state 15 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 14 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
The beta-tubulin folding intermediate I Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
20-539
100MG;ADP;AF3;
CCT G beta 5 complex closed state 0 Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT-G beta 5 complex closed state 7 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex intermediate state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-538
10016×ADP;
CCT G beta 5 complex close state 11 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 12 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 2 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT-G beta 5 complex closed state 6 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 13 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
The beta-tubulin folding intermediate IV Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
20-539
100MG;ADP;AF3;
CCT-G beta 5 complex closed state 4 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 9 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
The beta-tubulin folding intermediate II Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
20-539
100AF3;MG;ADP;
The beta-tubulin folding intermediate III Heteromer
P07437; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
20-539
100MG;ADP;AF3;
CCT G beta 5 complex closed state 1 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 10 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 3 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex best PhLP1 class Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT-G beta 5 complex closed state 8 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
CCT G beta 5 complex closed state 5 Heteromer
O14775; P17987; P40227; P48643; P49368; P50990; P78371; Q13371; Q99832;
19-538
10016×ADP; 16×MG; 16×AF3;
Human TRiC complex in closed state with nanobody Nb18, actin and PhLP2A bound Heteromer
P17987; P40227; P48643; P49368; P50990; P63261; P78371; Q99832; Q9H2J4;
19-538
10016×ADP; 16×MG; 16×AF3;
Human TRiC-PhLP2A complex in the closed state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832; Q9H2J4;
21-539
10016×ADP; 16×MG; 16×AF3;
Human TRiC/CCT complex with reovirus outer capsid protein sigma-3 Heteromer
P03527; P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
22-539
100ZN;
Human TRiC in ATP/AlFx closed state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
22-539
100
Human TRiC complex in closed state with nanobody bound (Consensus Map) Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
21-538
10016×ADP; 16×MG; 16×AF3;
Cryo-EM structure of human TRiC-tubulin-S1 state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
24-539
100.0ADP;
Cryo-EM structure of Human TRiC-ATP-open state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
24-539
100
Cryo-EM structure of human TRiC-NPP state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
24-539
100.0
Human TRiC open state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
24-539
100.0ADP;
Cryo-EM structure of human TRiC-tubulin-S2 Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
24-539
100.016×ATP;
cryo-EM structure of human TRiC-ADP Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
24-539
100.016×ADP;
hTRiC-hPFD Class3 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9;
26-539
100
hTRiC-hPFD Class6 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9;
26-539
100
hTRiC-hPFD Class5 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9;
26-539
100
hTRiC-hPFD Class1 (No PFD) Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
26-539
100
hTRiC-hPFD Class4 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9;
26-539
100
Human TRiC-PhLP2A complex in the open state Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832; Q9H2J4;
26-539
10010×ADP;
hTRiC-hPFD Class2 Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9;
26-539
100
Prefoldin-tubulin-TRiC complex Heteromer
O15212; O60925; P17987; P40227; P48643; P49368; P50990; P61758; P78371; Q99471; Q99832; Q9NQP4; Q9UHV9;
28-538
100ADP;
Human TRiC complex in open state with nanobody bound Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
28-538
100.016×MG; 16×ADP; 12×AF3;
Human CCT:mLST8 complex Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
30-539
100.0ADP;
Open state CCT-G beta 5 complex Heteromer
P17987; P40227; P48643; P49368; P50990; P78371; Q99832;
30-539
100.016×ADP;
The focused refinement of CCT4-PhLP2A from TRiC-PhLP2A complex in the open state Heteromer
Q9H2J4;
26-533
100

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
7nvn.1.Lmonomer0.7821-539
ADP;MG;AF3;100.00

2 SWISS-MODEL models built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 27nvn.1.Lmonomer0.7721-509
ADP;MG;100.00
Isoform 28ba9.1.Imonomer0.5526-509
21.38